Managed Healthcare Executive

Managed Healthcare Executive offers healthcare leaders in health plans and provider organizations valuable analysis, insights, and strategies aimed at achieving value-focused solutions.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#587364

United States

#200228

Health/Health

#3845

Traffic sources

Monthly visitors

Articles

Virtual Hospital-at-Home Program Cuts Costs but Needs Payment Reform

3 days ago | managedhealthcareexecutive.com | Briana Contreras

All-virtual, at-home acute care programs can lower costs for hospitals and payers, but broader adoption may require changes to reimbursement policies, according to a new study published in JAMA Network Open. Hospital-at-home care delivers medical staff, equipment and treatments—such as IV infusions—directly to patients’ homes. In the U.S., Medicare requires two in-person visits per day for reimbursement, which can be difficult to fulfill in large or high-traffic areas, according to study authors.
Women PCPs Have Equal or Better Medicare Patient Outcomes Than Men PCPs in Value-Based Care Model

3 days ago | managedhealthcareexecutive.com | Logan Lutton

Women primary care providers (PCPs) treating Medicare patients in a value-based care setting have equal or better patient outcomes than men PCPs in the same setting, despite having the same overall patient satisfaction rating, according to a recent study sponsored by agilon health, published May 16 in JAMA Health Forum.
Nonprofit Hospitals Drive Healthcare Costs, Report Finds

4 days ago | managedhealthcareexecutive.com | Briana Contreras

Nonprofit hospitals are a major driver of America’s rising healthcare costs, consuming over $1.5 trillion in 2023 due to inefficiencies, unclear pricing and executive excess, according to a new report by the Center for Medicine in the Public Interest (CMPI). While drug prices and insurance companies often draw scrutiny, the report shifts the spotlight to hospitals—particularly nonprofit systems—as the main contributor to inflating costs.
Retinal Disease Gene Therapy Field Remains Nascent Despite First Drug Approval

4 days ago | managedhealthcareexecutive.com | Ryan Flinn

Currently just two gene therapies have been approved to treat retinal diseases: Luxturna (voretigene neparvovec-rzyl) approved in 2017 to treat inherited retinal diseases with two mutations of the RPE65 gene, and the more recently approved Encelto (revakinagene taroretcel-lwey) to treat the progressive eye disease macular telangiectasia type 2 (MacTel). But the broader field of gene therapy research for retinal diseases remains stuck in early phases, according to a new study.
Research and Funding Essential to Improving Postpartum Hemorrhage Outcomes

4 days ago | managedhealthcareexecutive.com | Logan Lutton

Proper organizational structure is important to correctly respond to postpartum hemorrhage in the delivery room, methods that are funded by research, according to Abigail Wooldridge, assistant professor of Industrial and Enterprise Systems Engineering at the University of Illinois. The Trump administration’s focus on eliminating diversity, equity and inclusion (DEI) programs may challenge research funding.
Lurbinectedin and Atezolizumab Combo Improves Survival in Extensive-Stage Small-Cell Lung Cancer

1 week ago | managedhealthcareexecutive.com | Briana Contreras

A phase 3 trial published in The Lancet found that combining Zepzelca (lurbinectedin) with Tecentriq (atezolizumab) as first-line maintenance therapy for extensive-stage small-cell lung cancer (ES-SCLC) significantly improved survival outcomes compared to atezolizumab alone—though with a higher rate of side effects. Small-cell lung cancer (SCLC) is a fast-growing and aggressive form of lung cancer, accounting for about 15% of all lung cancer cases.
Extreme Weather Tied to Autoimmune Disease Flare-ups

1 week ago | managedhealthcareexecutive.com | Logan Lutton

Extreme weather events such as heatwaves, storms, wildfires or significant freezes that cause conditions like floods, power outages and air pollution caused an autoimmune disease flare in 12% of patients within 90 days of the event, according to research poster highlights presented by the Autoimmune Association at the National Health Council’s Science of Patient Engagement Symposium: Medicine, MedTech, and AI, held last month in Washington, D.C. The most common reason for a flare-up was the...
FDA Approves Dupixent as First Targeted Treatment for Bullous Pemphigoid in Adults

1 week ago | managedhealthcareexecutive.com | Briana Contreras

Today, the FDA approved Dupixent (dupilumab) as the first and only targeted therapy for adult patients with bullous pemphigoid (BP), a rare, chronic and painful inflammatory skin disease. This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and have limited treatment options.
With Lenacapavir 'You've Basically Got a Vaccine.' But Reaching the People Who Would Benefit Is Difficult, Says Gates Foundation Expert

1 week ago | managedhealthcareexecutive.com | Peter Wehrwein |Logan Lutton

In this interview with Managed Healthcare Executive, Peter Ehrenkranz, M.D., M.P.H., deputy director, HIV, at the Gates Foundation, discusses twice-a-year lenacapavir for HIV preexposure prophylaxis (PrEP). The FDA approved the preventive medication on June 18. Gilead Sciences is marketing it under the brand name Yeztugo. Ehrenkranz described Yeztugo as "really well tolerated, incredibly efficacious," and not requiring refrigeration.
Why Rural Healthcare Needs Smarter Tech and Better Policy

1 week ago | managedhealthcareexecutive.com | Briana Contreras

As the healthcare system faces the potential threat of Medicaid cuts, rural hospitals and communities may be among the hardest hit. In a recent conversation with Managed Healthcare Executive, Marcel Botha, founder and CEO of healthcare technology company 10XBeta, stressed that saving rural healthcare requires more than just policy—it demands on-the-ground innovation shaped by the people it’s meant to serve. “You cannot design new solutions in isolation,” Botha said.